BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Shanghai
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:CST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T165340
CREATED:20210312T064902Z
LAST-MODIFIED:20210312T065621Z
UID:29303-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development Europe
DESCRIPTION:In the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \n \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \n To know more about Gene Therapy Analytical Development Europe please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development-europe/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/8f5rxa
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T165340
CREATED:20210318T083358Z
LAST-MODIFIED:20210318T120953Z
UID:29402-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Inner Ear Disorders Therapeutics Summit – Digital Event
DESCRIPTION:Hearing loss has a huge impact on the quality of life for millions of people\, and as the average age of the population increases\, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important. \n \nThe Inner Ear Disorders Therapeutics Summit is gathering the world’s leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy\, cell therapy and small molecule-based approaches to treat inner ear disorders\, with the aim to progress the industry towards the first clinically approved therapy. \nJoin industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data\, identify the most appropriate biological endpoints and overcome the major challenges to develop safe\, effective\, and clinically viable inner ear disorder therapies to address the unmet medical need. \nTo know more about Inner Ear Disorders Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/inner-ear-disorders-therapeutics-summit-digital-event/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T165340
CREATED:20210203T103911Z
LAST-MODIFIED:20210203T103911Z
UID:28763-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:TCR-based Therapies Summit
DESCRIPTION:The TCR-based Therapies Summit is Dedicated to Supercharging TCR Design\, Translation & Manufacturing Strategy for Solid Tumor Success\nRunning digitally for 2021\, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity\, density & binding affinity for solid tumor indications. \n \nThis June (8-10)\, join this exclusive community online to virtually network and learn from the leading experts in pharma\, biotech and academia\, as we discuss how to how to overcome on-target off-tumor toxicity\, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy. \nNavigate across 3 days packed with dedicated\, interactive formats exploring the identification of novel targets\, the importance of safety profiling\, and discuss optimization of soluble approaches for the development of next-generation TCR-T products. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure. \nHelping Deliver Best-In-Class TCR Therapies\nJoin experts as they discuss the design\, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond. \n\nOptimizeyour TCR therapy approach\nExplorenovel combination strategies\nArmyour cells against the hostile tumor microenvironment\nImprovetarget selection and off-target validation\nExplorethe future of manufacturing for next-generation TCRs\n\n“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.” \nSteffen Walter\, Chief Scientific Office\, Immatics US
URL:https://www.pharmajournalist.com/event/tcr-based-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T165340
CREATED:20210312T065317Z
LAST-MODIFIED:20210312T065317Z
UID:29307-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:Next Generation Gene Therapy Vectors
DESCRIPTION:The inaugural Next Generation Gene Therapy Vectors meeting is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors. \n \nIndustry pioneers from cutting edge biotechs and world-leading academic vectorology groups including Dyno Therapeutics\, 4D Molecular Therapeutics and Generation Bio will share how ever-increasing clinical experience is guiding strategies to decrease the immunogenicity of vectors to allow durable transgene expression\, engineer vectors with lower toxicity at higher doses and use innovative technologies to optimise capsid\, transgene\, and promoter design. \nEverything in gene therapy starts with the vector\, so join this definitive\, niche\, digital conference to delve into the details of vector design\, engineering\, and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more about Next Generation Gene Therapy Vectors please click here.
URL:https://www.pharmajournalist.com/event/next-generation-gene-therapy-vectors/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210613
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T165340
CREATED:20210401T075326Z
LAST-MODIFIED:20210401T075326Z
UID:29614-1623542400-1623801599@www.pharmajournalist.com
SUMMARY:9th PREDiCT: Tumor Models Cell Therapy Summit
DESCRIPTION:With commitments to advancing your preclinical and translational oncology research\, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July. \nSee best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies. \nLearn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions\, predict toxicity and optimize dosing for patients. \nWhether you work in early discovery or late development\, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies. \nBelow are a few highlights you won’t want to miss! \n\nNovartisshare how to use a simple xenograft model to effectively assess CAR-T efficacy\nAstraZenecashows how to guide innovative clinical trials for cell therapies using preclinical data\nTakedadiscuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment\nHarvard Medical Schoolshare how they use multiple tumor models to advance NK cell therapies\n\nGet involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation. \nTo know more about 9th PREDiCT: Tumor Models Cell Therapy Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-predict-tumor-models-cell-therapy-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210614
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T165340
CREATED:20190206T211230Z
LAST-MODIFIED:20200330T122307Z
UID:19393-1623628800-1623801599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SMi are proud to announce the 5th annual conference:\nPre-Filled Syringes West Coast 2020\n14-15 June 2021\nSan Diego\, CA\, USA\nHyatt Regency Mission Bay\nwww.prefilled-syringes-westcoast.com/pjwl \nAssessing Device Development and Regulation for Advanced Innovation \nSMi is proud to present the 5th Annual Pre-Filled Syringes West Coast Conference in San Diego on 14th and 15th June 2021. \n \nFollowing the success of the last event\, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development\, device design\, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future. \nWith the global market for prefilled syringes estimated to exceed $9.7bn by 2025\, this year’s agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies\, case studies on device design and complex formulation\, life cycle and control strategies\, and innovations in connectivity and digital health. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nPLUS\, two interactive post conference workshops: \nWorkshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements\nHosted by Shannon Clark\, Principal\, UserWise\, Inc. \nWorkshop B: Postmarket safety reporting: The current regulatory environment with a global impact\nHosted by Khaudeja Bano\, Sr. Medical Director\, Abbott Molecular  \nKey Reasons to Attend: \n\nEngage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery\nDiscuss show to optimise current processes to align with global regulatory updates\nDelve into human factors engineering best practices\nUncover how industry is incorporating connectivity and digital health to optimise the user experience \n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nEarly bird deadlines: \n\nRegister by 28th February to save $400\nRegister by 31st March to save $200\nRegister by 30th April to save $100\n\n\nTo register or for more information visit: www.prefilled-syringes-westcoast.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210615
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T165340
CREATED:20210212T080535Z
LAST-MODIFIED:20210212T080535Z
UID:28924-1623715200-1623974399@www.pharmajournalist.com
SUMMARY:2nd RNAi-Based Therapeutics – Digital Summit
DESCRIPTION:As investments and collaborations hit a record high\, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases\, exciting efforts have now turned to a wide range of other diseases\, from CNS\, oncology\, metabolism and more. Despite the growing momentum\, much needs to be addressed in terms of targeted delivery\, safety\, and efficiency to fully unleash the therapeutic value of RNAi drugs. \n \nBuilt with large pharma and pioneering biotech insights\, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape\, extrahepatic delivery\, & PKPD for CNS\, oncology & beyond. \nWith a number of RNAi based clinical candidates emerging and excitement building in the field\, join the 2nd RNAi Based Therapeutic Summit 2021 – the comprehensive industry guide for senior biopharmaceutical leaders from discovery\, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need. \nTo know more about 2nd RNAi-Based Therapeutics please click here.
URL:https://www.pharmajournalist.com/event/2nd-rnai-based-therapeutics-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210616
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T165340
CREATED:20201020T102522Z
LAST-MODIFIED:20201020T102824Z
UID:27546-1623801600-1623974399@www.pharmajournalist.com
SUMMARY:Skin Microbiome Summit
DESCRIPTION:Skin microbiome products have been gaining more momentum in the last few years with more brands starting to develop products\, and personal care giants either starting to develop their own product or investing in start-ups focusing on these. It is a very exciting time for companies looking into this at the moment\, figuring out not only product development & formulation but also marketing strategy to raise more attention to this type of products. Despite huge popularity and early success stories\, there is still a need to learn more on topics such as: defining the skin microbiome\, formulating products\, cosmetics & pharma claims\, regulation for novel products\, latest advances in terms of mapping & profiling technologies\, as well as product testing. \n \nACI’s Skin Microbiome Industry Summit\, taking place on the 16th & 17th June 2021 in London\, will bring together the key actors of the industry to help the industry learn from one another\, work together to further grow and create new business opportunities. \nDuring the 2 days conference\, the participants will enjoy the various case studies presentations\, panel discussion\, Q&As and networking breaks to get the industry to thrive together. \nJoin us in London for a highly interactive & informative conference\, whilst enjoying the networking opportunities with your peers. \nMembers are entitled to a special discount on registration – to claim please contact Adamantia (Mado) Lampropoulou on MLampropoulou@acieu.net or +44 (0) 203 141 0607 quoting SSMe1MKTG.
URL:https://www.pharmajournalist.com/event/skin-microbiome-summit/
LOCATION:Park Plaza Westminster Bridge 200 Westminster Bridge Rd\, Bishop’s London\, SE1 7UT\, United Kingdom
ORGANIZER;CN="Active Communications International (ACI)":MAILTO:Mlampropoulou@acieu.net
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210619
DTSTAMP:20260515T165340
CREATED:20190131T121650Z
LAST-MODIFIED:20200608T143856Z
UID:19291-1623888000-1624060799@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology West Coast
DESCRIPTION:SMi’s 4th Pharmaceutical Microbiology West Coast Conference \nNovel approaches and best practices for tackling current industry contamination control challenges \nSMi’s 4th Annual Conference Pharmaceutical Microbiology West Coast\nNEW DATE: June 17 – 18\, 2021\nLocation: Hyatt Regency Mission Bay Hotel\, San Diego\, CA\, USA\nWebsite: http://www.pharma-microbiology-usa.com \n \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, Microcoat\, Millipore Sigma and Mettler Toledo \nCo-chairs Jim Polarine\, Senior Technical Service Manager\, STERIS Corporation & Geeta Singh\, Plant and Network Technical Specialist III\, Genentech \nFollowing on the success of the last West Coast event\, SMi proudly presents the 4th Pharmaceutical Microbiology West Coast Conference\, in San Diego\, USA\, on June 17th and 18th 2021 bringing microbiology experts to focus on innovations in rapid methods and contamination control strategies. Microbes such as bacteria\, fungi\, parasites and viruses that can contaminate current and novel pharmaceutical products or therapies may stem from various sources such as raw materials and human operators\, are taken into consideration. \nThis concern is critical in advanced products/therapeutics facilities where often distinct areas within manufacturing are slowly merging\, providing potential new sites for contamination events. The conference showcases sessions that cover alternative endotoxin testing and rapid mycoplasma testing as well as implementation of in-line biodurden monitoring to control water systems\, to name a few. Due to the complexities brought about by more advanced therapeutic products\, both drugs and patients are time dependent and rapid methods are ever more desired. \nA significant portion of the conference will focus on contamination control strategies and facilities support/novel technologies such as a look at a sustainable global contamination control program\, cleanroom pass thru best practices and a case study executing rapid transition from clinical to commercial manufacturing and more. Also see a regulatory session discussing objectionable organisms in non-sterile drug products and an all-women panel discussion: ‘culturing’ successful women microbiologists. \nEvent Hashtag: #SMiPharmaMicroWC \nKEY HIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscuss the guidance\, regulations and case studies for objectionable organisms in non-sterile drug products from ValSource\, Inc.\nGain insight into changing paradigms – moving to in-process testing from Johnson & Johnson\nExamine alternative endotoxin test methods for products exhibiting LER from Amgen\nExplore how to effectively scale up from clinical to commercial in three moves from Bristol-Myers Squibb\nJoin us for our first All-Women Panel Discussion on ‘Culturing’ successful women microbiologists\n\nPlus a half day interactive workshop on Wednesday\, June 16th 2021: \nAfternoon Workshop: Data Integrity in Environmental Monitoring: Causes and Solutions \nLed by: Ziva Abraham\, CEO\, Microrite and Morgan Polen\, SME\, Cleanroom Contamination Control Expert\, Microrite \nView the full agenda: http://www.pharma-microbiology-usa.com \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm\nEvent Hashtag: #SMiPharmaMicroWC\nLinkedIn: follow our company page – search ‘SMi Pharma’ \nADDITIONAL CONTACT INFO\nSimi Sapal – Marketing Manager\nPharmaceutical Division – SMi Group Ltd\nT: +44 (0)20 7827 6100\nE: ssapal@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-west-coast/
LOCATION:Hyatt Regency Mission Bay Hotel\, 1441 Quivira Road\, San Diego\, CA\, CA 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T165340
CREATED:20210617T072629Z
LAST-MODIFIED:20210617T072629Z
UID:30572-1623888000-1623974399@www.pharmajournalist.com
SUMMARY:6th Annual Oncolytic Virotherapy Summit
DESCRIPTION:In its most exciting year yet the field of oncolytic virotherapy has seen the highest number of clinical read-outs\, the emergence of next generation viruses\, and never-before-seen combination therapies. \nNow in its 6th year\, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest caliber of industry discussions\, The OV Summit will provide the roadmap to oncolytic virotherapy market success. \n \nUncover fresh studies from pharma and biotech companies of all sizes\, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. \nThis year’s Summit will help you to: \n\nUnderstand how viral backbone modification can achieve intravenous delivery\nHarness carefully selected payloads to achieve systemic effects\nScale virus production for commercialization\nThis year\, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings\, build a comprehensive network of like-minded peers who share the same challenges and search for the latest combination and genetic engineering strategies.\n\nJoin the leading minds in oncolytic virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies.
URL:https://www.pharmajournalist.com/event/6th-annual-oncolytic-virotherapy-summit/
LOCATION:Westin Copley Place\, 10 Huntington Ave\, Boston\, MA\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210622
DTEND;VALUE=DATE:20210625
DTSTAMP:20260515T165340
CREATED:20210315T105128Z
LAST-MODIFIED:20210315T105128Z
UID:29391-1624320000-1624579199@www.pharmajournalist.com
SUMMARY:HER2-Targeted Therapies Summit 2021
DESCRIPTION:Welcome to the Digital HER2-Targeted Therapies Summit 2021 – The First Conference Focused on Exploring New Frontiers of HER2 as a Pan-Tumor Target \nHER2 expressing patients are experiencing drug resistance\, suboptimal duration of response and refractory/relapsed disease\, stimulating new frontiers for HER2-targeted drug development. Impressive clinical data are being reported for next-generation anti-HER2 approaches in breast\, gastric\, lung\, colon cancers and beyond. However\, efforts to expand the clinical utility of HER2 as a pan-tumor target don’t stop there\, with a flood of news on priority reviews\, fast track approvals\, IPOs and collaborations. \nAs such\, the HER2-Targeted Therapies Digital Summit 2021 arrives as the first ever cross-disciplinary meeting for large pharma\, biotech and academia\, to maximize HER2-targeting in the pantumor setting. Expect to be involved in interactive discussions on the diversity of next generation anti-HER2 drugs in the clinic including ADCs\, bispecifics\, TKIs\, CAR approaches & more. \nThis is your chance to overcome challenges of resistance against anti-HER2 approaches and accelerate therapies to patients in need. Examine HER2 heterogeneity across different tumors to maximize the commercial potential of this target. Discuss how quantitative pathology is helping to match HER2 expression with therapeutic response. \nAs the clinical and commercial growth potential of next generation HER2-targeted therapies becomes apparent\, this is a timely and comprehensive forum giving you the opportunity to connect with leaders of the field directly. \nBe part of this unique forum to strengthen your pipeline by expanding the clinical utility of your anti-HER2 candidate across tumor settings with the greatest unmet medical need. \nTo know more about HER2-Targeted Therapies Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/her2-targeted-therapies-summit-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20210622T150000
DTEND;TZID=Asia/Shanghai:20210622T190000
DTSTAMP:20260515T165340
CREATED:20210602T080240Z
LAST-MODIFIED:20210602T080240Z
UID:30412-1624374000-1624388400@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China E-Trade Season- Sino-India Pharmaceutical Exchange
DESCRIPTION:CPhI & P-MEC China has launched the “E-Trade Season 2021” from March to June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. One of the themed sessions\, named Sino-India Pharmaceutical Exchange\, will be focusing on Indian & Chinese pharma markets\, with online learning and trading opportunities. \nThe live stream webinar will look into policies\, trends and practice\, etc. of both Chinese and Indian pharma markets\, covering topics including Development Trend of China’s API Industry and Cooperation Prospect with India\, Requirements and Practical Procedures of Imported Drug Registration in China\, and Development of Indian APIs and Generic Drugs in Indian and Chinese Market\, with guest speakers from China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)\, China Chinopharma Limited\, and Dr. Reddy’s Laboratories. \nThe webinar is FREE for anyone to register and attend. Registered attendees will receive access to the webinar.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-e-trade-season-sino-india-pharmaceutical-exchange/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:tinny.yao@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210628
DTEND;VALUE=DATE:20210701
DTSTAMP:20260515T165340
CREATED:20210402T091212Z
LAST-MODIFIED:20210406T095308Z
UID:29618-1624838400-1625097599@www.pharmajournalist.com
SUMMARY:3rd Annual Blood-Brain Barrier Summit
DESCRIPTION:Now in its 3rd year\, the Blood-Brain Barrier Summit is the industry’s definitive blood-brain barrier conference\, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers. \nBuilding on the success of last year’s meeting\, this year’s program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies\, nanoparticle engineering\, AAV capsids\, focused ultrasound\, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry. \nAs we gather the best minds in this ever-challenging field\, from the likes of AbbVie\, Novartis\, Roche\, Merck and Ossianix\, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists. \nTo know more about 3rd Annual Blood-Brain Barrier Summit please click here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-summit-2021/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T165340
CREATED:20210301T091950Z
LAST-MODIFIED:20210301T091950Z
UID:29192-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit
DESCRIPTION:Close the Clinical Gap\, Discover the Next Generation of Microbiome-based Therapeutics\, and Establish New Partnerships to Accelerate Your Research \nThe advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics. \nThere is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic\, key functions are beginning to be understood and the number of clinical candidates are increasing. However\, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit. \n \nThe Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nFrom understanding microbiome functionality\, leveraging lessons from clinical development and scaling manufacturing processes\, through to leveraging microbiome biomarkers for patient stratification and diagnostics\, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics. \nThere is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients\, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization. \nTo know more about 6th Microbiome Movement – Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T165340
CREATED:20210309T092319Z
LAST-MODIFIED:20210309T092319Z
UID:29289-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Since the start of the 20th century\, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave\, multispecific medicines\, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins\, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. \n \nAs such\, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. \nJoin 100+ thought leaders of Chemically Biology\, Screening Biology and Molecular Biology from the likes of Amgen\, Ranok Therapeutics\, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge\, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. \nTo know more about Induced Proximity-Based Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/induced-proximity-based-drug-discovery-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T165340
CREATED:20210312T075616Z
LAST-MODIFIED:20210312T080030Z
UID:29331-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:JAK Inhibitors Drug Development Summit
DESCRIPTION:Returning to the digital stage this summer\, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology\, rheumatology\, gastroenterology\, oncology and hematology. \nFocusing on optimized selectivity\, drug-drug interactions\, safety and efficacy challenges\, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors. \nEnsure you attend this conference to learn\, to network and to strengthen your pipeline\, and implement the right clinical strategy.
URL:https://www.pharmajournalist.com/event/jak-inhibitors-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210630
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T165340
CREATED:20210331T084111Z
LAST-MODIFIED:20210331T110431Z
UID:29602-1625011200-1625183999@www.pharmajournalist.com
SUMMARY:3rd Cell Engager Summit
DESCRIPTION:The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \nThis forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising. \nIf you are part of a research team that is looking to accelerate the approval of cell engager therapies\, then this conference has been curated with you in mind. \nBelow are a few highlights you won’t want to miss: \n\nDrive efficacy in solid tumors with solid tumor targets addressed by Roche\, Amgen\, Pfizer\, Merus\, andCompass Therapeutics\nModulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor\, Harbour Biomed\, Crescendo Biologics\, Pieres\,and Aptevo\nHarness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck\, Lava Therapeutics\, Verseau Tx\, andoNKo-Innate\nImproving the therapeutic window of cell engagers – addressing toxicity\, half-life\, and CRS withAmunix\, Synaffix\, Revitope\, and TeneoBio\n\nTo know more about 3rd Cell Engager Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-cell-engager-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T165340
CREATED:20210302T095204Z
LAST-MODIFIED:20210302T095204Z
UID:29214-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:ARDS Drug Development Summit 2021
DESCRIPTION:The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS\, emergence of novel targets\, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS\, but broader\, systemic inflammation. \nVirtually uniting dedicated and experienced industry experts from Aqualung\, Bone Therapeutics\, Boehringer Ingelheim\, Athersys and more\, this trailblazing new meeting will help you overcome your most urgent drug development challenges.
URL:https://www.pharmajournalist.com/event/ards-drug-development-summit-2021/
LOCATION:Virtual
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T165340
CREATED:20210312T065852Z
LAST-MODIFIED:20210312T065852Z
UID:29308-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:mRNA Based Therapeutics Summit
DESCRIPTION:The mRNA-Based Therapeutics Summit will unite the world leaders developing mRNA therapeutics to discuss learnings\, challenges and future directions concerning translation and manufacturing of your novel mRNA modality. From mRNA vaccine development for infectious disease and oncology\, effective mRNA gene therapies and novel delivery strategies\, we bring to you an all-inclusive platform dedicated to accelerating successful translation of mRNA into a transformative class of medicines.  \nTo know more about mRNA Based Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T165340
CREATED:20210312T072425Z
LAST-MODIFIED:20210312T072425Z
UID:29325-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:Non-Small Cell Lung Cancer Drug Development Summit
DESCRIPTION:The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. \nThis is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency\, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies\, either in combination or monotherapies. \n \nAs checkpoint inhibitors are on the brink of entering the perioperative setting and the approval of novel bispecifics with dual oncogenic targeting\, this forum will enable you to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards. \nJoin Global Innovators To: \n\nLeverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement\, best application strategies and potential combination partners with AstraZeneca\, Puma Biotechnology\, Cullinan Oncology and Takeda\nUnravel the potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie\, Merus\, Black Diamond\, AOM Biosciences and Mirati Therapeutics\nDive into the exciting advancements in the NSCLC rare mutations space\, with the novel therapies in targeting BRAF\, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals\, Elevation Oncology and Boeringer Ingelheim\nHarness the power of the immune system to treat NSCLC by delving into the current best\, novel targets and combination strategies to improve patent outlook with Merck & Co\, Immutep\, BerGenBio and Bristol-Myers Squibb\nAdvance the efficacy of companion diagnostics and look to the future of early disease detection\, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS\, Takeda\, Novartis\, BloodPAC and Amgen\nA deep-dive workshop explores how to utilize EGFR-targeting in solid tumors outside of NSCLC with Maverick Therapeutics\, Black Diamond Therapeutics and Harvard Medical School\n\nNetwork with 100+ executive biopharma leaders over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer\, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
URL:https://www.pharmajournalist.com/event/non-small-cell-lung-cancer-drug-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210714
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T165340
CREATED:20210514T083527Z
LAST-MODIFIED:20210514T084615Z
UID:30155-1626220800-1626393599@www.pharmajournalist.com
SUMMARY:GxP Cloud Compliance Summit
DESCRIPTION:Develop & implement your practical roadmap to migrate your GxP regulated applications to the cloud with regulatory\, security & partner selection guidance.  \nEstablish robust documentation practices to maintain CFR 11 compliance\, accurately assess data security risks for migrating to cloud infrastructure & select the right partner to ensure sustained continuous compliance. \nNothing is more important in the pharmaceutical and life sciences industries than patient safety and meeting regulations. This past year and the global disruption have highlighted how life sciences organizations need to respond to radical shifts through digitization. The 2nd GxP Cloud Compliance Summit will return to discuss the next steps following initial feasibility study and implementation – designed to help you achieve GxP regulated security\, privacy\, transparency and compliance at any scale when migrating to the cloud. \nWith 18 trailblazing stories from AbbVie\, Orchard Therapeutics\, AWS\, USDM\, Chef/Progress\, we will share practical takeaways from CFR21 part 11 to mapping out data migration to selecting the right cloud providers. Across 2 days\, you will gain the tools to streamline processes\, facilitate on demand scalability\, increase efficiency and reduce costs. \nThis is the only dedicated industry-led meeting focused on GxP cloud adoption in the life sciences industry\, join us this July to learn how to overcome the barriers of GxP cloud compliance\, increase knowledge for data-powered business and empower collaboration between your organization and platform partners – providing a much more efficient operation and effective infrastructure to support your research and clinical activities. \nFind out more >>> https://ter.li/xv45we
URL:https://www.pharmajournalist.com/event/gxp-cloud-compliance-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210719
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T165340
CREATED:20210312T071709Z
LAST-MODIFIED:20210312T071709Z
UID:29322-1626652800-1626911999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Returning digitally in 2021\, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! \nFocusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation\, this is not one to miss as you seek to accelerate the development of your neurological gene therapy. \nDiscover the latest neurological targets\, familiarise yourself with the European landscape\, and debate and discuss with the leading minds of the field from the likes of UCB\, Lysogene\, UniQure and AskBio\, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s\, Parkinson’s and epilepsy. \n \nFocusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field\, this year’s 3-day agenda has been developed alongside neurological experts from AskBio\, Handl Therapeutics\, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field. \nDiscussing rare to common neurological disorders\, attend the digital meeting in July to: \n\nHear the latest clinical updates from the most advanced companies to inform your future strategies\nDiscover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities\nDiscuss how to optimise the use of preclinical models and biomarkers for improved translation and reduced risk to patients\nAsk the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disorders\nWeigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery\nRaise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programs\nBe a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses\n\nDon’t miss your opportunity to benchmark against your competitors\, hear the state of the art technology advances and research in the field\, and make new connections at the last digital European meeting\, to revolutionise the development and delivery of your neurological gene therapy.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-neurological-disorders-europe/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T165340
CREATED:20210208T085452Z
LAST-MODIFIED:20210208T085452Z
UID:28862-1626739200-1626911999@www.pharmajournalist.com
SUMMARY:In-House Impact: Life Sciences
DESCRIPTION:In-House Impact: Life Sciences is a new type of forum\, designed for and by legal leaders in the Life Sciences\, to help legal teams move from enterprise defenders to enablers of innovation and cross-functional competency. \nThis conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences. \nWe guarantee that your time out of the office and money are well spent. With thought-provoking case studies\, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers\, we’ve no doubt this strategic discussion will leave you feeling inspired to make big change. \nTo know more about In-House Impact: Life Sciences please click here.
URL:https://www.pharmajournalist.com/event/in-house-impact-life-sciences/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T165340
CREATED:20210322T111844Z
LAST-MODIFIED:20210322T111844Z
UID:29474-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Cell-Mediated Therapies for Infectious Disease Summit
DESCRIPTION:In the fight against emerging coronavirus variants\, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells. \nThe Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. See more – https://ter.li/bo7qq7 \nJoin over 80 industry and academic leaders pioneering this new paradigm of research\, and for the first time discuss novel advances in t-cell epitope-directed vaccines\, as well as CAR-T\, TCR and NK cell therapies designed to provoke durable immunity. \nWith strategic insight and clinical advances shared from Gilead\, Merck\, Vaccibody\, TScan Therapeutics and more\, join the discussion to assess: \n\nBioinformatic tools to identify immunogenic targets\nVaccine design and delivery to trigger strong T cell responses\nBridge the gap from translatable preclinical models to IND approval\n\nLeave this meeting with a greater understanding of next-generation approaches to target\, prevent and cure HIV\, EBV and SARS-CoV-2 infection. \nSee more – https://ter.li/bo7qq7
URL:https://www.pharmajournalist.com/event/cell-mediated-therapies-for-infectious-disease-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T165340
CREATED:20210414T091907Z
LAST-MODIFIED:20210414T091907Z
UID:29789-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Next Generation Food Allergy Drug Development
DESCRIPTION:In the context of dramatically increasing food allergy incidence and a breakthrough approval in the field\, the Next Generation Food Allergy Drug Development Summit will unite large pharma and innovative biotechs to overcome the unique drug development challenges involved in turning promising food allergy biologics into clinical and commercial realities. \nJoin us to investigate the latest technological innovations\, benchmark against your peers\, build global connections and streamline your drug development pipelines for food allergy\, with insights being shared from a range of companies and institutions including Prota Therapeutics\, Allergy Therapeutics\, Intrommune\, Vedanta Biosciences and University of North Carolina. \nTo know more about Next Generation Food Allergy Drug Development please click here.
URL:https://www.pharmajournalist.com/event/next-generation-food-allergy-drug-development/
LOCATION:Online | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T165340
CREATED:20210329T142632Z
LAST-MODIFIED:20210329T142632Z
UID:29572-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy Immunogenicity Summit
DESCRIPTION:The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate\, measure and predict immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges\, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on the latest approaches to predict\, measure and overcome every immunogenicity challenge you encounter. \nFocused specifically on examining gene therapy immunogenicity\, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory approaches could enable re-dosing and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing approaches to address immunogenicity. \nJoin your peers online and discover: \n\nHow Chameleon Bioscience are developing an immune evasive AAV for repeat dosing\nThe impact of innate and anti-transgene immunogenicity on AAV vector-mediated gene transfer with Genethon\nStrategies to monitor anti-AAV cell-based transduction inhibition assay supporting clinical trials with Sangamo Therapeutics\nPerformances of biosafety analytical assays commonly used in gene therapy development\nImmunogenicity risk assessment for AAV-based gene therapies with Roche\nHow to define the seroprevalence and titer of pre-existing antibodies with age and geographical location with Novartis\nAAV capsid neutralizing antibodies and associated complement mediated immunotoxicties with IU Edu\nRegulatory considerations for immune responses to gene therapies with the US FDA\nRole of innate immunity in CD8+ T cell responses in AAV gene transfer with The NIH\nMitigation of AAV vector immunogenicity with tolerogenic nanoparticles with Selecta Bioscience\n\nView the full event guide now to find out more!
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-immunogenicity-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210803
DTEND;VALUE=DATE:20210806
DTSTAMP:20260515T165340
CREATED:20210416T073855Z
LAST-MODIFIED:20210416T073855Z
UID:29797-1627948800-1628207999@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement – Skin Health & Dermatology Summit
DESCRIPTION:Translating Scientific Findings of the Skin Microbiome into Commercially Viable Therapeutics & Cosmetic Products That Improve Skin Health \nWith improvements in the tools and technologies that enable deeper analysis of the skin microbiome\, the community’s understanding of the skin microbiome is becoming clearer. This has led to the development of a number of breakthrough dermatological\, skincare and cosmetic solutions that tap into this ecosystem on our skin for improved health. \nHowever\, there still exists several unique areas of basic and clinical science within the skin microbiome field that need addressing before the true potential of this field is realized. \nCelebrating our fourth year\, the Microbiome Movement – Skin Health & Dermatology Summit continues to unite researchers from academia and industry to address the unique areas of scientific R&D\, as well as the consumer interfacing aspect of this industry. Bringing together 25+ expert speakers and 100+ key decision makers across 3 days\, we will hasten the development of microbiome-targeting therapeutics and cosmetics through a series of presentations\, panel discussions and networking opportunities. \nJoin us to fast-track the development of microbiome-targeting therapeutics and cosmetics that focus on characterization\, clinical testing and product commercialization. \nTightly focused on translating academic discussions into cosmetic and therapeutic development\, this unrivalled program addresses the latest scientific findings and key translational challenges to aid the development of your scientifically validated skin microbiome products so you can bring them to the hands of patients and consumers faster.
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-skin-health-dermatology-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210817
DTEND;VALUE=DATE:20210820
DTSTAMP:20260515T165340
CREATED:20210409T153003Z
LAST-MODIFIED:20210413T084608Z
UID:29760-1629158400-1629417599@www.pharmajournalist.com
SUMMARY:Prostate Cancer Drug Development Digital Summit
DESCRIPTION:The inaugural virtual Prostate Cancer Drug Development Summit lands at a crucial time as the first and only dedicated conference for large pharma\, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery\, translation\, and clinical development of safe and effective treatments for prostate cancer. \n \nHere’s a sneak peek of crucial topics to be addressed: \n\nAmgen examining Bi-specific T-cell engager immune therapies for the treatment of prostate cancer ​​​​​​\nNovartis and Advanced Accelerator Applications revealing PSMA\, re-envision survival\n​​​​​​Noxopharm evaluating whether Veyonda is the answer to safe and effective prostate cancer treatment\nThe National Cancer Institute and the National Institutes of Health teaching optimization potential role for immunotherapy in biochemically recurrent prostate cancer\nThe University of Texas\, MD Anderson Cancer Center demonstrating strategies for overcoming the immunosuppressive prostate tumor microenvironment and whether there is still a role for chemotherapy and chemotherapy combinations\n\nTo find out more and view the 2021 speaker line-up\, download the full event guide. \nJoin 60+ thought-leaders converging at the first industry-led meeting to gain the latest scientific insights with renowned Urologists/Oncologists and those striving to advance safe and effective therapeutic breakthroughs to patients in need. \nTo know more about Prostate Cancer Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/prostate-cancer-drug-development-digital-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210817
DTEND;VALUE=DATE:20210820
DTSTAMP:20260515T165340
CREATED:20210514T082011Z
LAST-MODIFIED:20210514T084343Z
UID:30139-1629158400-1629417599@www.pharmajournalist.com
SUMMARY:Integrin-Targeted Drug Discovery Summit
DESCRIPTION:The excitement surrounding integrins has been growing over the past few years\, culminating in recent clinical success\, innovative biology and medicinal chemistry advancements blazing the way to tackle previously undruggable disease modalities through novel integrin targets \nThe Integrin-Targeted Drug Discovery Summit is not just the first\, but the only industry-driven event sharing pioneering advances\, expert insights and exclusive updates on the field of integrin drug discovery and development – from solid tumors to autoimmune diseases\, from ophthalmology to fibrosis\, revealing the therapeutic windows of integrins! \nWith the vast potential of integrins as targets\, this inaugural 3-day summit will unite industry trailblazers including Pliant Therapeutics\, Morphic Therapeutics and 7 Hills Pharma with academic leaders\, such as pioneer Dean Sheppard\, to delve into the biology and chemistry of different integrins classes\, MoA and explore the best approach to regulate integrins\, driving translational and clinical success. \nJoin a global community of 80+ experts on August 17-19 to tackle issues of safety\, selectivity and specificity in drug development\, further your understanding of the structure and function of integrins to inform your R&D decisions and leverage the lessons learned over the past 20 years to enhance your bed to bedside progression. \nFind out more >> https://ter.li/g4kols
URL:https://www.pharmajournalist.com/event/integrin-targeted-drug-discovery-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210824
DTEND;VALUE=DATE:20210827
DTSTAMP:20260515T165340
CREATED:20210507T084054Z
LAST-MODIFIED:20210507T084054Z
UID:30057-1629763200-1630022399@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Alzheimer’s Disease Summit
DESCRIPTION:The 2nd Annual Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement. \nBack for its 2nd year\, there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape. This industry-defining meeting delves into blood-based biomarkers\, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge\, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s Disease. \nThe Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science\, convey lessons learned and network to build long lasting partnerships. \nTo know more about 2nd Annual Biomarkers for Alzheimer’s Disease Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-alzheimers-disease-summit/
LOCATION:Online Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR